Liraglutide: Weight Loss, Dosing, & Safety Info

개요

Liraglutide는 비만 치료제로 승인된 최초의 GLP-1 수용체 작용제입니다. 매일 주사를 맞아야 하지만 15년 이상의 안전성 데이터가 축적되어 있으며, 현재는 제네릭 의약품으로도 이용 가능합니다.

Key Information

Mechanism

GLP-1 수용체 작용제로서 13시간의 반감기를 가지며 매일 투여가 필요합니다. 주 1회 투여 제제와는 달리 혈중 약물 농도에 최고치와 최저치가 나타납니다.

Benefits

• 6.4-8.0% 체중 감량
• 15년 이상 안전성 데이터
• 제네릭 이용 가능
• 소아 승인

Side Effects

• 메스꺼움 (39%)
• 설사 (21%)
• 구토 (16%)
• 매일 주사 투여 필요

Contraindications

• Medullary thyroid carcinoma
• MEN2 syndrome

Evidence Summary

SCALE 시험(참가자 5,000명), LEADER 시험(환자 9,340명, MACE 13% 감소).

Research

SCALE 시험에서는 6.4-8.0%의 체중 감소가 나타났습니다. LEADER 시험에서는 제2형 당뇨병(T2D) 환자에서 MACE가 13% 감소한 것으로 나타났습니다.

Safety

15년 이상의 시판 후 안전성 데이터. 갑상선 C-세포 종양에 대한 동일 계열(class) 박스 경고 적용.

Liraglutide: Weight Loss, Dosing, & Safety Info

Liraglutide was the first GLP-1 receptor agonist approved for obesity. It requires daily injection but has 15+ years of safety data and is now available as a generic.

Key Information

• Also known as: Saxenda; Victoza
• Sequence: GLP-1(7-37) with C16 fatty acid
• CAS number: 204656-20-2
• Molecular formula: C172H261N43O53
• Half-life: 13 hours
• Administration: subcutaneous injection
• Dose range: 0.6-3.0 mg daily
• Price range: $1.5–$15.0/mg
• Storage: refrigerated 2-8C
• Reconstitution: pre-filled pen, no reconstitution needed
• US status: FDA-approved (generic available)
• Legal status: FDA-approved as Saxenda (weight) and Victoza (diabetes). Generic available since 2024.
• Research papers: 5 indexed

Mechanism

GLP-1 receptor agonist with 13-hour half-life requiring daily dosing. Produces peak and trough drug levels unlike weekly formulations.

Benefits

• 6.4-8.0% weight loss
• 15+ years safety data
• Generic available
• Pediatric approval

Side Effects

• Nausea (39%)
• Diarrhea (21%)
• Vomiting (16%)
• Daily injection required

Contraindications

• Medullary thyroid carcinoma
• MEN2 syndrome

Evidence Summary

SCALE trials (5,000 participants), LEADER trial (9,340 patients, 13% MACE reduction).

Research

SCALE trials showed 6.4-8.0% weight loss. LEADER trial showed 13% MACE reduction in T2D patients. View the research papers indexed on our research page.

Safety

15+ years post-marketing safety data. Same class boxed warning for thyroid C-cell tumors.

Legal Status

FDA-approved as Saxenda (weight) and Victoza (diabetes). Generic available since 2024.

Frequently Asked Questions About Liraglutide

What is Liraglutide?

Liraglutide is a GLP-1 receptor agonist also known as Saxenda and Victoza. It is a first-gen GLP-1 agonist requiring daily injection, now available as a generic. It is studied for its potential therapeutic applications and is available from various research chemical vendors.

How does Liraglutide work?

GLP-1 receptor agonist with 13-hour half-life requiring daily dosing. Produces peak and trough drug levels unlike weekly formulations.

What is the recommended dosage for Liraglutide?

The commonly studied dosage range for Liraglutide is 0.6-3.0 mg daily. Dosage protocols vary based on research objectives. Always consult published studies and start with conservative amounts. Liraglutide should only be used in controlled research settings.

Where can I buy Liraglutide?

PepsReview indexes Liraglutide pricing from multiple vendors. Check the Vendors tab above for a price comparison table showing cost per milligram, purity, COA status, and stock availability. Vendor reviews from real users are available on each vendor's profile page.

Is Liraglutide legal?

US regulatory status: FDA-approved (generic available). FDA-approved as Saxenda (weight) and Victoza (diabetes). Generic available since 2024.

What are the side effects of Liraglutide?

Reported side effects include: nausea (39%), diarrhea (21%), vomiting (16%), daily injection required. Always review safety data and published studies before use.

Key Research Papers on Liraglutide

The following peer-reviewed studies and clinical trials are indexed in our research library for Liraglutide. Each paper links to a short summary with key findings, study design, and publication data.

• Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial — JAMA, 2015 (1650 citations)
• A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — N Engl J Med, 2015 (1650 citations)
• Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined — N Engl J Med, 2021 (750 citations)
• Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial — JAMA, 2022 (600 citations)
• Liraglutide for Children 6 to <12 Years of Age with Obesity — A Randomized Trial — N Engl J Med, 2025 (200 citations)

Related Weight Loss / Metabolic Peptides

Other peptides in the weight loss / metabolic category that may be of interest for comparative research:

• Semaglutide — GLP-1 receptor agonist for weight loss and diabetes management
• Tirzepatide — GIP + GLP-1 dual agonist, once-weekly injectable
• Retatrutide — Triple agonist (GLP-1/GIP/Glucagon), next-gen weight loss
• Survodutide — Dual GLP-1/glucagon agonist in development
• AOD-9604 — Modified growth hormone fragment for fat burning

Key Research Papers on Liraglutide: Weight Loss, Dosing, & Safety Info

The following peer-reviewed studies and clinical trials are indexed in our research library for Liraglutide: Weight Loss, Dosing, & Safety Info. Each paper links to a detailed summary with key findings, study design, and publication metadata.

• Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial — JAMA, 2015 (1650 citations)
• A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — N Engl J Med, 2015 (1650 citations)
• Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined — N Engl J Med, 2021 (750 citations)
• Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial — JAMA, 2022 (600 citations)
• Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial — N Engl J Med, 2025 (200 citations)

Related Weight loss / Metabolic Peptides

Other peptides in the weight loss / metabolic category that may be of interest for comparative research: